In-Process Controls & Sampling Audit Readiness
Verify your in-process control programme covers every CPP, sampling plan, and acceptance criterion FDA investigators expect
Overview
What's Inside
In-process controls are a direct window into manufacturing process understanding. FDA investigators use 21 CFR 211.110 to verify that written procedures describe the controls and examinations performed on appropriate samples of in-process materials — and that these controls are actually followed in practice. Weak in-process programmes signal a fundamental lack of process understanding and are among the most frequently cited production system observations.
This checklist is built from real FDA 483 observation patterns — including failure to establish adequate written procedures for production and process controls, failure to examine in-process samples to confirm conformance with specifications, inadequate process parameter setup for ensuring product quality and consistency, and in-process materials held beyond validated hold times without retesting. Each section maps observations to specific CFR requirements, recommended corrective actions, and the evidence investigators expect.
It covers eight critical domains: in-process control governance and SOP framework, CPP identification and control strategy linked to CQAs, sampling plan design with statistical rationale, in-process testing methods and acceptance criteria, contemporaneous documentation and data integrity, hold time validation and intermediate material controls, Quality Unit oversight and batch disposition, and trending with CAPA integration.
Why It Matters
In-process control deficiencies are consistently cited in FDA production system 483 observations. Investigators specifically look for CPPs that are not linked to product CQAs, sampling plans without statistical justification, and acceptance criteria that are not pre-defined before production starts. Failure to follow written in-process control procedures is a direct 21 CFR 211.110 violation and signals systemic process control failures.
What's Covered
Sections in this checklist
- In-process control SOPs, regulatory alignment, roles, responsibilities, and training programme
- CPP identification, CQA linkage, risk assessment, and control strategy documentation
- Sampling plan design, statistical rationale, sample locations, and chain of custody
- In-process test methods, acceptance criteria, and OOS handling procedures
- Contemporaneous recording, GDP compliance, ALCOA+, audit trails, and 21 CFR Part 11
- Hold time study design, intermediate storage conditions, and identity controls
- Quality Unit review scope, batch yield reconciliation, and discrepancy investigation
- In-process trend analysis, statistical process control, CAPA linkage, and management review
Who It's For
Target roles
Regulatory Basis
21 CFR 211.110, 21 CFR 211.100, 21 CFR 211.192, 21 CFR 211.103, 21 CFR Part 11, FDA Process Validation Guidance (2011), ICH Q8, ICH Q9, ICH Q10, EU GMP Chapter 3, FDA Compliance Program 7356.002
Download In-Process Controls & Sampling Audit Readiness
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Related Checklists
Batch Record Review & Disposition Audit Readiness
Comprehensive 140+ point audit checklist for pharmaceutical batch production record management covering master batch record control, contemporaneous documentation and GDP compliance, in-process controls and yield calculations, Quality Unit production record review, equipment documentation, labeling and reconciliation, training, electronic systems and data integrity, and trending — grounded in real FDA 483 observation patterns under 21 CFR 211.188 and 211.192.
Process Validation Lifecycle Audit Readiness
Comprehensive 150+ point audit checklist for pharmaceutical process validation covering the FDA three-stage lifecycle model — Process Design (Stage 1), Process Qualification (Stage 2), and Continued Process Verification (Stage 3) — plus revalidation triggers, in-process controls, microbiological contamination controls, and validation documentation aligned with the FDA 2011 Process Validation Guidance and 21 CFR 211.100/211.110.
Equipment Cleaning Validation Audit Readiness
Comprehensive 140-point audit checklist for pharmaceutical equipment cleaning validation covering HBEL/MACO acceptance limit determination, worst-case equipment and product grouping, cleaning SOP adequacy, swab and rinse sampling strategy, analytical method validation, dirty and clean hold time studies, and lifecycle change control — grounded in real FDA 483 observation patterns under 21 CFR 211.67 and the EMA HBEL Guideline.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
